Navigation For Mobile

Archives

Small Pharma Steps Up

Here’s some good news, courtesy of DCAT Value Chain Insights: “Smaller bio/pharmaceutical companies are accounting for an increasingly larger portion of new products as measured by recent new molecular entity…

Posted in drug discovery, drugs, FDA | Tagged , , , , | Comments Off on Small Pharma Steps Up

Blockbuster Drugs Hang On: Is a Post-Blockbuster World in Sight Yet?

“Blockbuster” drugs — typically defined as those that generate annual sales of $1 billion or more — have been the lifeblood of Big Pharma company revenues since Smith, Kline and French’s…

Posted in blockbuster, drugs | Tagged , , , | Comments Off on Blockbuster Drugs Hang On: Is a Post-Blockbuster World in Sight Yet?

The Unblockbuster – Speeding Cures with Specialty Drugs

For years, industry soothsayers have suggested the imminent demise of blockbuster drugs was upon us (here’s one from 2009 – Goodbye blockbuster medicines; hello new pharmaceutical business models). But two…

Posted in blockbuster, CRO/CMO, drugs, generic, Orphan drug | Tagged , , , | Comments Off on The Unblockbuster – Speeding Cures with Specialty Drugs

Big Pharma Keeps Getting Bigger…by Shrinking?

An article at Pharma Manufacturing (Shrinking Big Pharma) pointed to the recent movement among Big Pharma towards smaller production floors. It comes as no surprise. With the rise of target-based…

Posted in generic, Uncategorized | Tagged , , | Comments Off on Big Pharma Keeps Getting Bigger…by Shrinking?